Article Information
History
- April 28, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- H Arasanz1,2,†,
- A Bocanegra1,
- I Morilla2,3,
- J Fernández-Irigoyen4,
- M Martínez-Aguillo2,3,
- L Teijeira2,3,
- M Garnica1,
- E Blanco1,5,
- L Chocarro1,
- K Ausin4,
- M Zuazo1,
- G Fernández-Hinojal6,
- M Echaide1,
- L Fernández-Rubio1,
- S Piñeiro-Hermida1,
- P Ramos1,
- L Mezquita7,8,
- D Escors1,†,*,
- R Vera2,3,* and
- G Kochan1,*
- 1Oncoimmunology Group, Navarrabiomed. Instituto de Investigación Sanitaria de Navarra (IdiSNA). Irunlarrea st., 3. 31008, Pamplona, Spain
- 2Medical Oncology Department, Hospital Universitario de Navarra. Instituto de Investigación Sanitaria de Navarra (IdiSNA). Pamplona, Spain
- 3Oncobiona Group, Navarrabiomed. Instituto de Investigación Sanitaria de Navarra (IdiSNA). Pamplona, Spain
- 4Clinical Neuroproteomics Unit, Proteomics Platform, Proteored-ISCIII. Navarrabiomed. Instituto de Investigación Sanitaria de Navarra (IdiSNA). Pamplona, Spain
- 5Gene Therapy and Regulation of Gene Expression, Centro de Investigación Médica Aplicada (CIMA). Instituto de Investigación Sanitaria de Navarra (IdiSNA). Pamplona, Spain
- 6Medical Oncology Department, Hospital Clínico San Carlos. Madrid, Spain
- 7Medical Oncology Department, Hospital Clínic i Provincial de Barcelona, IDIBAPS. Barcelona, Spain
- 8Medical Oncology Department, Laboratory of Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS. Barcelona, Spain
- ↵†Corresponding author(s): HA, hugo.arasanz.esteban{at}navarra.es; DE, david.escors.murugarren{at}navarra.es